Drug Trial Radar · NCT02474589
A Trial to Assess the Safety, Tolerability, and Pharmacokinetics of the Anti-Orthopoxvirus Compound Tecovirimat
Last checked: Nov 19, 2026Latest source record: Sep 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
449
Actual
Start
Jun 19, 2015
Primary completion
Aug 24, 2016
Study completion Aug 24, 2016
Sponsor
- Lead sponsor
- SIGA TechnologiesIndustry
- Sponsor type
- Industry
- Collaborators
- Biomedical Advanced Research and Development Authority
- First posted
- Jun 18, 2015
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Multicenter, double-blind, placebo controlled, Phase 3 study to determine the safety and tolerability of oral tecovirimat, an anti orthopoxvirus compound, in subjects.
Conditions
- Smallpox
Interventions
tecovirimatDrug
Study is based on Animal Regulatory Rule
PlaceboOther
Does not apply
Primary outcomes
What the sponsor says the trial is designed to measure.
- To Determine the Number of Participants With Adverse EventsTime frame: 45 days
Locations
11 sites in 1 country. Site status is shown where the registry gives one.
Coastal Clinical Research, Inc.
Mobile, Alabama
Paradigm Research
Redding, California
Paradigm Research
San Diego, California
Johnson County Clinical Trials
Lenexa, Kansas
Heartland Research Associates, LLC
Newton, Kansas
Center for Pharmaceutical Research
Kansas City, Missouri
Sundance Clinical Research LLC
St Louis, Missouri
Meridien Clinical Research
Omaha, Nebraska
Medical Research South
Charleston, South Carolina
Benchmark Research
Austin, Texas
Benchmark Research
Fort Worth, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.